ArticleAdvanced healthcare materials2025
Synergistic Combination of Tamoxifen-Tetraphenylethylene Co-Assembled Micelles and Orlistat-Induced Lipid Droplet Inhibition to Overcome Tamoxifen Resistance.
Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Protein palmitoylation in hematological malignancies: mechanistic links to lipid metabolic reprogramming and therapy resistance.Frontiers in immunology · 2026Review
- Orlistat: a comprehensive review of a lipase inhibitor from obesity management to emerging oncological applications.Frontiers in pharmacology · 2026Review
- Synergistic Combination of Tamoxifen-Tetraphenylethylene Co-Assembled Micelles and Orlistat-Induced Lipid Droplet Inhibition to Overcome Tamoxifen Resistance.Advanced healthcare materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nanostructured supramolecular materials enable the precise control of biological interactions by tuning structural features such as size, shape, and surface charge, allowing targeted cellular uptake, optimized biodistribution, and enhance therapeutic efficacy. Despite its clinical success, tamoxifen (TMX) therapy faces challenges, such as drug resistance development; a key resistance mechanism involves intracellular lipid alterations. Lipid droplets (LD) play a crucial role in cancer progression and resistance to therapy. However, the direct suppression of LD formation as a synergistic adjunct to enhance TMX delivery remains underexplored. In this study, a supramolecular micelle platform based on amphiphilic tetraphenylethylene derivatives are presented with tunable oligoethylene glycol (OEG) side-chain lengths. By modulating the OEG length, micelles with distinct surface charges are developed that significantly improve intracellular the TMX delivery to LDs. Furthermore, this system enabled visualization of intracellular drug distribution via intrinsic fluorescence. This targeted delivery reveales that LD-mediated TMX sequestration is a resistance mechanism in estrogen receptor-positive breast cancer. Importantly, co-treatment with orlistat, an LD formation inhibitor, disrupted this resistance pathway and markedly enhance TMX efficacy of TMX. This dual-functional approach, combining organelle-specific delivery and LD modulation, constitutes a powerful supramolecular strategy to overcome TMX resistance and advances the development of next-generation cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.